In Oct 2007, the FDA declared that the labeling for all PDE5 inhibitors, like tadalafil, needs a additional outstanding warning with the potential threat of sudden hearing reduction as the result of submit-marketing and advertising reviews of short term deafness connected with use of PDE5 inhibitors.[19]This article has incorrect info This post doe